Other studies indicated that some interleukins, especially IL-19, act as mediators in breast cancer [8, 9], where high disease-specific survival (DSS) and metastasis-free survival (MFS) were noticed in patients with low levels of IL-19 compared with patients with high levels of IL-19 [10]. This evidence concerns the gene IL19 and breast carcinoma.